Table 4. Univariate and multivariate Cox regression analyses of disease-free survival.
| Parameter | Univariate analysis | Multivariate analysis* | ||||
|---|---|---|---|---|---|---|
| HR | 95% CI | p-value | HR | 95% CI | p-value | |
| CD133 (+ vs. -) | 2.72 | 1.39-5.34 | 0.004 | - | - | - |
| ALDH1 (+ vs. -) | 1.92 | 0.95-3.88 | 0.069 | - | - | - |
| Tumor size (> 2 cm vs. ≤ 2 cm) | 4.13 | 1.71-9.96 | 0.002 | - | - | - |
| LN status (N1-3 vs. N0) | 4.95 | 2.37-10.37 | < 0.001 | - | - | - |
| Stage | < 0.001 | - | - | <0.001 | ||
| I vs. III | 0.062 | 0.02-0.21 | 0.07 | 0.02-0.22 | ||
| II vs. III | 0.23 | 0.11-0.47 | 0.23 | 0.11-0.49 | ||
| ER (+ vs. -) | 1.78 | 0.91-3.49 | 0.095 | - | - | - |
| PR (+ vs. -) | 1.78 | 0.88-3.61 | 0.109 | - | - | - |
| Histologic grade (G3 vs. G1-2) | 1.99 | 0.98-4.02 | 0.055 | - | - | - |
| HER2 (+ vs. -) | 1.73 | 0.78-3.82 | 0.178 | - | - | - |
| Luminal (nonluminal vs. luminal) | 1.63 | 0.81-3.29 | 0.175 | - | - | - |
| TNBC (TNBC vs. non-TNBC) | 1.42 | 0.66-3.04 | 0.370 | - | - | - |
| RTx (+ vs. -) | 1.51 | 0.68-3.37 | 0.311 | - | - | - |
| CTx† (+ vs. -) | 3.27 | 0.19-55.6 | 0.413 | - | - | - |
HR=hazard ratio; CI=confidence interval; ALDH1=aldehyde dehydrogenase 1; LN=lymph node; ER=estrogen receptor; PR=progesterone receptor; HER2=human epidermal growth factor receptor 2; TNBC=triple-negative breast cancer; RTx=radiotherapy; CTx=chemotherapy.
*Stepwise method; †FIRTH method.